CXCL12 and melanoma: Treatment with blocking antibodies targeting CXCR4, the receptor for SDF-1, VEGF-A or IL-6, has been shown to reduce melanoma cell invasiveness induced by the conditioned media from hypoxic activated fibroblasts [129].